2025, the Year AcuSurgical Reached New Heights
- Amélie Saraby
- 2 days ago
- 3 min read
A look back at a pivotal year of growth, structure, and clinical validation
There are years that profoundly transform a company.Years when intuition turns into confirmation, when a prototype becomes a reliable platform, when an agile mindset evolves into a solid organization.
For AcuSurgical, 2025 was that pivotal year.
A year marked by a dual movement — technical and human — that redefined the company’s trajectory. Because bringing robotics to the heart of vitreoretinal surgery requires more than innovation: it requires building, structuring, aligning, and growing.And that is exactly what happened.
A Climb in Credibility for a Robot That Is Changing the Game
On the international scientific stage, Luca® reached a new level of recognition.Presented at AAO in Orlando, Euretina in Paris and other local conferences, the robot drew the attention of leading vitreoretinal surgeons — a field where stability, finesse, and repeatability are measured in microns.
In 2025, several key opinion leaders traveled to Montpellier to test the platform firsthand:
Prof. Eric Souied, Head of the Department of Ophthalmology, CHI Créteil, France: “The precision is remarkable. The potential is immense.”
Prof. Dr. Matthias Becker, Director of Stadtspital Zürich: “The intuitive control and impressive stability of Luca®.”
Dr. Tarek Alasil, vitreoretinal surgeon based in Los Angeles, CA, USA: “I would use it in routine as soon as it reaches the market.”
Prof. Souied, Prof. Becker and Dr. Alasil testing Luca® in Montpellier — 2025
These unanimous and enthusiastic responses confirmed — for the team and for the scientific community — that robotics has its place in retinal surgery, and that Luca® is opening the way.
A New Internal Rhythm: Connecting, Clarifying, Synchronizing
Developing a robot designed for the human eye requires extreme precision.Bringing it to the operating room requires an even more precise organization.
In 2025, AcuSurgical took an important step in its natural evolution: from a fast-growing start-up into a company entering its next phase of maturity, moving closer to clinical delivery.
The implementation of squads helped strengthen collaboration and clarity across teams. Each R&D team — System, Hardware, Software, Test — found its place within a dynamic that offered shared clarity on objectives, roles, and interactions.
As one Engineer put it: “As a squad, we don’t discover decisions downstream — we build them together.”
These squads are the rope connecting talents:the one that prevents slipping,that sets the pace,that helps the team move forward together despite steep technical challenges.
As a RA/QA Manager notes: “We’re speaking the same language.”
All teams from R&D, RA/QA, Product and Clinical have continued to grow and structure their work, enabling the company to approach the next steps with a reinforced stability and alignment.
Technical Progress: Scaling a Decisive Wall
One of the most important moments of the year was the robot’s design freeze.
After an intense year during which R&D tackled major technical challenges, the teams reached a long-awaited point: a moment marking the transition from development to consolidation.
This milestone strengthened the foundation for the next clinical steps — particularly the upcoming FIH-2 — by reinforcing system stability and enabling the preparation of the verification phase, following the successful completion of FIH-1 in 2024.
As summarized by Cécile Genevieve, R&D Director:
“We had to make choices, define trade-offs, structure requirements, integrate new talents, and adopt new methods — all within a tight schedule.”
This collective effort now enables AcuSurgical to approach 2026 with a more mature, more reliable robot — ready to enter the crucial verification phase, with FIH-2 planned for 2026.
A Demanding Year, Fueled by Exceptional Energy
If one had to summarize 2025, perhaps the best words would be those of Arnaud Tellier, VP Product Strategy:
“A year where clinical expertise met technological innovation, in an atmosphere of genuine collaboration.”
Smiles around a robot,
heated discussions during a test,
friendly evenings where the team reimagined the world (and sometimes the algorithm).
These are the moments — simple, authentic — that best illustrate AcuSurgical in 2025.
A culture built on collaboration, mutual support, humility… but also pride. The pride of advancing a project that matters. The pride of welcoming surgeons from around the world. The pride of seeing Luca® gain credibility. The pride of opening a new chapter in ophthalmic robotics.
After 2025… Continuing the Ascent
Everything structured, built, and consolidated in 2025 now leads to major steps where LUCA must demonstrate robustness, repeatability, and adoption in multiple surgical environments.
Beyond that, one ambition remains intact:
bringing Luca® into operating rooms
offering surgeons an unprecedented level of precision
providing patients with a new standard of care
AcuSurgical is not just a visionary start-up.It is a company in motion, a united team, a rope climbing each wall, one after another.
The ascent continues.And 2026 already promises to be a decisive step.
